Further to DrugAlert volume 737, HPS Pharmacies wish to give notice that Clinect is continuing to experience a supply interruption for Imdur® and Monodur® as follows:

Imdur® Durules
Isosorbide mononitrate 120mg
ARTG 62795 

Monodur® Durules
Isosorbide mononitrate 120mg
ARTG 64284

Normal supplies of Imdur® and Monodur® 120mg tablets are expected to resume by late March 2023.

The Therapeutic Goods Administration (TGA) made a Serious Scarcity Substitution Instrument (SSSI) to help manage this long-term out of stock situation. The SSSI allows pharmacists to substitute registered medicines containing 60mg of isosorbide mononitrate in a modified-release tablet while the 120mg tablets are unavailable.

This SSSI has been extended to 30 June 2023, unless revoked earlier by the TGA. Points to consider during this time include:

  • The quantity supplied to a patient under the SSSI must match the total dose prescribed;
  • The SSSI may not be used to substitute medicines if the prescriber has indicated on the prescription that substitution is not permitted; and
  • The patient, or the person acting on their behalf, must consent to the substitution.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Clinect on (03) 9918 5555 or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates